RxDoctor Payments Data

Douglas Welsh, MD

Cardiovascular Disease · Norfolk, NENPI 1336196161

Payments from drug & device makers

$711in general payments, 2019–2025

Across 44 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$132
  • Amgen$114
  • Johnson & Johnson$105
  • Abbott$83
  • E.r. Squibb & Sons, L.L.C.$74
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$58
  • plus $145 from 6 others

What the payments were for

  • Food & beverage$711100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$711 in reported general payments places this provider in the 20th percentile of 97 cardiovascular disease providers in Nebraska.

See all cardiovascular disease providers in Nebraska

Medicare billing

Part B allowed, 2024
$59,731
Medicare patients
374
Services billed
973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban359$278,931
Repatha SureclickEvolocumab73$59,012
EntrestoSacubitril/Valsartan37$44,679
XareltoRivaroxaban55$35,894
MultaqDronedarone Hcl19$28,302
Bisoprolol Fumarate449$17,912
Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide373$13,617
Losartan Potassium889$13,172
Nitroglycerin PatchNitroglycerin172$11,687
Doxazosin Mesylate380$10,127
Praluent PenAlirocumab20$9,856
Potassium Chloride380$9,592
Rosuvastatin Calcium562$6,197
Ranolazine ErRanolazine38$5,906
Atorvastatin Calcium488$4,296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$132$278,931359 claims
NovartisEntresto$55$44,67937 claims
Johnson & JohnsonXarelto$105$35,89455 claims
Arbor Pharmaceuticals, Inc.Edarbi$12$3,25413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 97 cardiovascular disease providers in Nebraska.

Other cardiovascular disease in Norfolk

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →